Cystic fibrosis: management and monitoring of respiratory manifestations An overview of the pharmacological management of respiratory symptoms in people with cystic fibrosis to ensure they can optimise benefit from their medication regime.…
Medicines regulator approves UK’s first dual combination inhaler for mild asthma AstraZeneca said the marketing authorisation meant its Symbicort Turbohaler 200/6 could be used by 2.7 million adults in the UK who live with mild asthma.…
Government advisers recommend autumn COVID-19 boosters for people at most risk An extra booster dose may also be offered in the spring for smaller groups, such as people who are immunocompromised or of older age.…
Some patients switched to ‘greener’ inhalers without consultation, say experts Exclusive: Experts warn that non-consented inhaler switches pose risks to patients' health and advise physicians to carry out individual inhaler checks to avoid this.…
NHS develops dashboard to identify possible over-prescribing of prednisolone The dashboard calculates the total cumulative dose of prednisolone prescribed to patients in England in the past 12 months, allowing those at risk to be considered for alternative treatment methods.…
Half of asthma patients in the UK overusing SABAs, study finds In a UK asthma programme, 284,683 out of 574,913 patients were found to be “potentially overusing” short-acting β2-agonists.…
Chronic obstructive pulmonary disease: diagnosis and management Early diagnosis and medicines optimisation are fundamental to ensure timely and appropriate treatment of chronic obstructive pulmonary disease and improve a patient’s quality of life.…
Personalised medicine approach could benefit people with asthma Prescribing asthma treatment based on genetic differences could improve outcomes, results presented at the European Respiratory Society International Congress have suggested.…
Novel once-daily fixed-dose ICS–LABA improves lung function over ICS monotherapy, research finds A once-daily fixed-dose combination of inhaled corticosteroids and long-acting β2-adrenoceptor agonist significantly improved lung function over inhaled corticosteroids alone, a phase III study has concluded.…
Once-daily ICS-LABA-LAMA superior to ICS-LABA in improving lung function, research suggests A study in The Lancet Respiratory Medicine indicates that ICS-LABA-LAMA once daily is better than ICS-LABA in improving lung function.…